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Introduction
Pneumonia accounts for 1.3 million hospitalizations 
annually, and of those admissions, 36 to 66 percent (%) 
have pleural effusions (1). Patients are typically treated 
with antibiotics, drainage of the pleural fluid, and either 
intrapleural administration of fibrinolytic agents or 
operative drainage (2). Fibrinolytic agents are intended to 
break up loculations in the infected pleural space and allow 
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re-expansion of the lung (1,2). Mortality increases from 7% 
to 33% as effusions evolve, leading to progressive sepsis 
and shock (1). We report the use of alteplase in the pleural 
space to decrease hospital stay, surgical interventions, and 
complications. The objective of the study is to determine 
the efficacy of thrombolytics for the management of 
complex pleural fluid collections.
Methods
An institutional review board (IRB) approved retrospective 
chart review was performed of all consecutive patients 
treated at a single institution from July 01, 2007 to 
November 01, 2012. The IRB ID number was 5130004. 
The study was retrospective review and a waiver of 
informed consent was approved by the IRB. 
We examined all patients treated with alteplase for 
loculated pleural fluid collections. Baseline patient 
demographics, co-morbidities, smoking history, antibiotic 
use, alteplase dose, number of days utilizing alteplase 
therapy, and chest tube output after instillation were 
recorded. All pleural fluid collections were class 5 or greater 
as described by Light (3); although, not all effusions were 
related to infection. Treatment endpoints were: (I) days to 
resolution of pleural fluid collection; (II) time to surgery; 
and (III) mortality.
The protocol is: 6 mg of alteplase in 50 mL of normal 
saline instilled via a pleural chest tube. The chest tube is 
clamped for 4 hours (dwell time); then, unclamped and 
allowed to drain. One dose was given per 24 hour period, 
for a total of three doses. Patients were evaluated with plain 
chest radiographs (CXR) and chest computed tomography 
(CT) prior to alteplase therapy and a CXR was performed 
daily prior to repeat additional instillations. Patients who 
showed complete clearance on the CXR after any dose 
were considered to be adequately treated and additional 
doses of alteplase were not given. Patients with a persistent 
opacification on CXR after the third dose had been drained, 
underwent a CT scan of the chest. Success of treatment 
was determined by resolution or near resolution of the fluid 
collection(s) on CT chest imaging. Patients with persistent 
loculated effusions were considered to have failed medical 
treatment and underwent decortication. Persistent loculated 
effusions were determined based on the surgeons’ analysis 
and read of the CT chest imaging. If the effusion was 
equal to the size of the image prior to administration of 
the effusion, it was considered unresolved and surgery was 
indicated. If the effusion was significantly large, though, 
decreased in size from the initial effusion, it was considered 
unresolved and surgery was indicated. Surgery was not 
indicated if the effusion was significantly resolved, based 
on the surgeon read of the imaging. The chest tube used 
ranged from 8.5, 28 and 32 F chest tubes depending on 
surgeon preference and size of the pleural effusion. 
Statistical analysis was performed utilizing SAS software 
to determine factors associated with failure of alteplase 
therapy. Patient factors such as co-morbidities, history of 
recent trauma, prior lung disease, history of lung cancer, 
and smoking history were examined utilizing t-test and 
statistical significance was assumed if P<0.05. 
Results
One hundred and three [103] consecutive patients were 
identified who received alteplase therapy for management 
of loculated pleural fluid collections. The age of the patients 
ranged from 20–91 y (mean 57.2 y); 68 (66%) were male. 
The most common co-morbidity was hypertension (55%, 
n=60), and 35% (n=32) of patients had a history of smoking. 
Additionally, 8 (7.7%) of patients had a previous history of 
lung cancer, and 7 (6.8%) had a history of lung surgery. Of 
patients with loculated pleural fluid collections, 20 (18.2%) 
had a history of recent trauma (Tables 1,2).
Eight-two patients (79.6%) had a loculated pleural fluid 
collection secondary to an empyema, and 21 (20.4%) had 
a retained hemothorax. Of the 21 patients with a retained 
hemothorax, 16 were secondary to blunt trauma with rib 
fractures as the most common injury in 14 of the 16 trauma 
patients. Penetrating trauma and malignant hemothorax 
accounted for the remainder of the retained hemothoraces. 
A third of the patients with a retained hemothorax became 
secondarily infected. Three of the 21 patients with retained 
hemothoraces died, caused by empyema, aspiration 
pneumonia, and massive hemothorax. 
Ninety-six patients (93.2%) were treated with antibiotics; 
7 patients were not treated with antibiotics, and all had a 
diagnosis of a retained hemothorax. The most common 
antibiotics used were vancomycin (n=64), piperacillin/
tazobactam (n=60),  f luoroquinolones (n=58),  and 
cephalosporins (n=58); 86 patients were prescribed more 
than one antibiotic (Table 3).
The average length of  stay (LOS) from day of 
admission to discharge for was 25.9 days (3–143 days). 
The average number of days in the hospital for the 
diagnosis of a hemothorax and empyema was 21.9 and 
26.9 days respectively (Table 3). Forty patients (36.4%) 
1312 Heimes et al. Thrombolytics
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(5):1310-1316jtd.amegroups.com
had follow-up visits, with a mean time to follow of 12 days 
(range, 2–28 days). For the 103 patients reviewed, there 
were 110 hemothoraces with installment of alteplase 
via the chest tube. The average time from diagnosis to 
alteplase treatment for a hemothorax was 12.8 days (range, 
1–32 days); and 16.2 days (range, 4–48 days) for an 
empyema. Patients with a history of lung disease had a 
statistically significant shorter time from diagnosis to TPA 
therapy; mean 9.4 days compared to 16.3 days for patients 
without lung disease (P=0.009). 
The mean number of days on alteplase therapy was 
2.2±1.4 days, (range, 1–11 days). The average chest tube 
output after day 1 was 509.8, after day 2 was 456.6 and 
after day 3 was 445.8 (Figure 1). Eighty-seven (79.1%) had 
their chest tube removed prior to discharge. The average 
time from alteplase completion to chest tube removal was 
5.7±4.5 days (range, 1–21 days). Eleven patients (10.7%) 
underwent decortication; of which 5 had a retained 
hemothorax and 6 had a loculated pleural effusion. After 
completion of alteplase therapy, the average time to 
discharge was 10.2 days (range, 1–109 days). The average 
time from completion of alteplase therapy to discharge 
in the hemothorax and empyema groups was 6.9 and 
11.1 days, respectively (Table 4). 
Seventeen patients (16.5%) died; 3 patients (14.3%) died 
Table 1 Patient characteristics
Variables n (%)









Diabetes 26 (25.5)/76 (74.5)
Hypertension 56 (54.9)/46 (45.1)
Lung disease 25 (24.5)/77 (75.5)
COPD 15 (14.7)/87 (85.3)
Asthma 12 (11.8)/90 (88.2)
Smoking 43 (41.7)/60 (58.3)
Trauma 20 (19.4)/83 (80.6)
Hemothorax 23 (22.8)/78 (77.2)
Effusion 101 (98.1)/2 (1.9)
Empyema 81 (83.5)/16 (16.5)
Table 2 Patient characteristics
Variables Hemothorax (%) Empyema (%) Total (%)
N 21 (20.4) 82 (79.6) 103
Average age 53.9 58.1 57.2
Trauma 16 (76.2) 4 (4.9) 20 (19.4)
DM 4 (19.0) 24 (29.3) 28 (27.2)
COPD 3 (14.3) 12 (14.6) 15 (14.6)
Tobacco use 7 (33.3) 37 (45.1) 44 (42.7)
HTN 12 (57.1) 48 (58.5) 60 (58.3)
Table 3 Treatment for effusion
Variables n (%)
Number of patients with effusion 101
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in the hemothorax group, while 14 patients (17.1%) died 
in the empyema group. The cause of death was: sepsis (4), 
respiratory failure (5), aortic injury causing hemorrhage (1), 
cardiac arrest (1), aspiration (1), and progression of 
malignancy (1). The patient who died of an aortic injury 
presented as trauma patient with a massive left hemothorax 
after a high speed motor vehicle collision. The patient 
developed a retained hemothorax; TPA was administered 
and the chest tube drained 2.5 liters of sanguineous fluid. 
The patient was transferred to the intensive care unit. The 
patient had a cardiac arrest in the intensive care unit and was 
emergently taken to the operating room for an exploratory 
left thoracotomy. Three liters of bright red blood and clots 
was evacuated from the chest. The autopsy demonstrated an 
undiagnosed aortic laceration secondary to rib fractures of 
ribs 9 and 10. The hematoma was stable for 9 days and the 
patient became unstable after the administration of TPA. 
The TPA probably removed the clotted blood that had 
caused a tamponade of the injury. He died in the operating 
room. 
Discussion and conclusions
Fibrinolytics have been used in the intrapleural space 
as a means to break up the loculations that occur as the 
physiological response to parapneumonic effusions and 
allow re-expansion of the lung (1,2,6-9). Inflammation 
and the presence of mesothelial cells in the pleural space 
bring about the fibrinopurulent phase, where the effusion 
becomes infected and there is an imbalance between 
coagulation and fibrinolysis (5,6). Fibrinolysis is inhibited, 
causing deposits to occur along the pleura, resulting in 
loculations and an empyema (6).
Fibrinolytics such as streptokinase and urokinase were 
the first agents used to activate the fibrinolytic system and 
activate plasminogen directly (3,5-7,10,11). These actions 
allow for the dissolution of fibrin complexes present in 
the parapneumonic effusion or empyema (6). TPA acts to 
break up the fibrinous debris, allowing drainage of fluid (5). 
The half-life of TPA in the blood is only 6 minutes and is 
undetermined in the pleural space, therefore the appropriate 
dwell, amount, and timing of TPA is still undetermined (6). 
The efficacy of fibrinolytics in loculated pleural effusions 
and empyemas has been questioned in the literature. A 
double blind randomized study by Maskell and colleagues in 
the New England Journal of Medicine found that intrapleural 
administration of streptokinase does not improve mortality, 
the rate of surgery, or the length of hospital stay (2,6). This 
study randomized patients to placebo or control groups, 
with control groups receiving 250,000 IU of streptokinase 
diluted in 30 mL of normal saline delivered into the pleural 
space every 12 hours for 6 doses total. There was a slightly 
higher number of adverse events in the streptokinase group 
in Maskell’s study, but this was not a statistically significant 
difference (P=0.08) (2). 
A Cochran review concluded that fibrinolytic therapy 
showed benefit by reducing need for surgical intervention 
despite the 2005 trial by Maskell (7). Stefanutti et al. 
reported success with intrapleural instillation of urokinase 
in pediatric patients using weight adjusted doses (8). Only 
4 of 41 patients required further operative treatment for 
parapneumonic effusions (8). Furthermore, Thommi and 
colleagues found that alteplase was significantly more 
effective than placebo in reducing surgical interventions 
in patients with empyemas (1). In this study, 95 percent 
of patients received adequate drainage and treatment, 
compared to 12 percent in the placebo group (1).
Froudarakis and colleagues performed a prospective 
study in twenty patients with intrapleural administration of 
recombinant TPA for parapneumonic effusions or persistent 
pleural effusions (5). They found a 95% success rate with 
the use of intrapleural TPA, with improved drainage after 
instillation, decrease in inflammatory mediators such as 
white blood cells and CRP, and minimal complications (5). 
Complications were described as mild pain with instillation 
and mild, local hemorrhage in 3 of 20 patients (5). 
A retrospective review of 118 patients found successful 
treatment of parapneumonic and pleural effusions in 69.5 
percent of patients treated with one to eight doses of 25 mg 
of alteplase diluted in 120 mL of saline and instilled into 
the intrapleural space. Intrapleural alteplase was successful 
Table 4 Hemothorax and empyema
Variables Hemothorax Empyema Total
N 21 82 103
Surgery 5 (24%) 6 (7.3%) 11 (10.7%)
Mortality 3 (14.3%) 14 (17.1%) 17 (16.5%)
Total days in hospital 
average
21.9 26.9 25.9
Time from TPA  
completion to  
discharge (days)
6.9 11.1 10.2
Complications 1 2 3
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in 78.1 percent of empyemas, 61.5 percent of patients with 
hemothoraces, 100 percent of those with malignancy as a 
cause of the pleural process, 71.4 percent of complex pleural 
effusions, and 48 percent of parapneumonic effusions. 
Success was determined by resolution or near resolution of 
the fluid collection on imaging with avoidance of surgical 
intervention. The overall effectiveness of alteplase was 
86.4 percent, with the highest success rate noted after 
one or two doses. Patients who required more than two 
doses were more likely to have residual disease, suggesting 
operative intervention should be considered after two doses. 
Unsuccessful treatment occurred in 35 patients, seven of 
these patients experienced bleeding requiring operative 
intervention. Bleeding was associated with empyema in 
6.3 percent, malignancy in 12.5 percent, complex pleural 
effusion in 4.8 percent, and parapneumonic effusion in 8 
percent (9). This comparatively high rate of bleeding may 
result from higher dosing used in that study.
Rehman and colleagues (12) randomized patients to 
receive placebo, TPA, DNase or TPA plus DNase. They 
found no difference between placebo and TPA with respect 
to avoiding surgical deloculation. When DNase was added 
to TPA, only 4% were referred for surgical intervention 
when followed over a three month period. A 1 hour dwell 
time with 10 mg of TPA was used twice daily (12).
Surgical management remains an option in the 
management of empyema and at one point was considered 
the gold standard (13). Chen and colleagues reviewed 
thoracoscopic management of 101 pediatric empyemas in 
their institution (4). In their study the median duration of 
time from diagnosis of empyema to surgical management 
was 4 days, however, 35.6 percent first underwent 
thoracostomy tube placement followed by thoracoscopic 
management. The median duration of chest tube duration 
was 6 days with a range between 1 and 28 days. Chen and 
colleagues noted increased difficulty with surgery when a 
chest tube was placed preoperatively, noted by statistically 
significant increased operative time in the thoracostomy 
tube group (94 versus 72 minutes). Primary treatment with 
thoracoscopy was performed in 65 percent of patients. In 
this study 32.7 percent were treated in the intensive care 
unit preoperatively, which was associated with a prolonged 
hospital stay. The median duration of hospital stay 
postoperatively in this study was 13 days (4).
St Peter and colleagues performed one of the first 
prospective studies comparing thoracoscopic and 
intrapleural fibrinolytics in children (13). In this study 18 
children were randomized to fibrinolysis versus surgical 
management. The results showed similar outcomes in 
regards to post treatment LOS, days of oxygen support, 
time to defervescence, and analgesia. A statistically 
significant difference was found between the hospital 
charges between the patient groups. The surgical group 
averaged $11,700 in hospital charges versus $7,600 for 
the fibrinolysis group. Only three patients (16.6 percent) 
failed fibrinolytic therapy in this study, requiring surgical 
thoracoscopy for definitive management. In the surgical 
group, two of the patients became clinically worse, 
requiring ventilator support, progression of sepsis, and 
requiring temporary hemodialysis, while no progression of 
disease occurred in the fibrinolytic group (13).
Sonnappa et al. had similar results in their prospective 
randomized trial for children with empyema, comparing 
thoracoscopic decortication compared to intrapleural 
fibrinolysis with urokinase (10). There was no difference in 
time to discharge after intervention between the fibrinolytic 
and surgical group. Their surgical group were able to 
remove the chest drain 1 day earlier than the fibrinolytic 
group (P=0.055). Only 2 of the patients in the fibrinolytic 
therapy group required thoracoscopic surgery for definitive 
management. The surgical group had a 25 percent increase 
in cost compared to the fibrinolytic therapy group, similar 
to the findings of St Peter (10,11).
Surgical therapy is not without risks. In elderly patients 
with multiple co-morbidities, mortality can be up to 5 
percent in thoracoscopic surgery and 10 percent with 
decortication. Recurrence of empyema can occur in up to 
2.6 percent of patients treated surgically. Complications 
can occur, including bleeding, infection, intolerance to 
single lung ventilation, re-expansion pulmonary edema, 
prolonged ventilation, intercostal neuralgia, air leaks, 
and bronchopleural fistulas. Postoperative pain can cause 
additional problems, especially in the elderly patients (1).
In our study, the average hospital stay was 25.9 days, 
with the diagnosis of loculated pleural fluid collection or 
empyema was diagnosed later in the hospital course. The 
delay in treatment, was secondary to all of these patients 
were referred and the thoracic surgery service was the 
consulting service. As the treatment protocol was refined, 
and conversations were had with the referring services, the 
time to referral for treatment decreased. Only 10.7 percent 
of these patients failed thrombolytic treatment, requiring 
surgical decortication. This is inferior to the results of 
Rehman et al. when DNase was added but far superior to 
their results for TPA alone. They found that only 4% of 
patients were referred for surgery. This was when patients 
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were followed over three months. We referred no patients 
for surgery after hospital discharge. They found no 
difference from placebo when TPA was used alone. This 
may have been related to their short dwell time, implying 
that dwell time may be more important than higher doses, 
10 mg, in this case, more frequent administration and 
perhaps even the addition of DNase. Their results may 
also have been adversely affected by their reliance on 
changes in plain radiography to assess effectiveness. In our 
experience, plain radiography is insufficiently sensitive 
and can lead to confusion between residual effusion and 
residual parenchymal consolidation. In our study, TPA 
led to near complete resolution of the effusion when CT 
was used to evaluate effectiveness. We also utilized a much 
more truncated time schedule, referring patients for surgery 
after failure at three days, rather than over a period of three 
months.
Those patients with a known history of lung disease 
had a statistically significant earlier time to diagnosis and 
initiation of fibrinolytic therapy. Those patients may have 
been monitored more closely because of their known 
comorbidity. Overall, the data shows that a significant 
number of patients with class 5–7 pleural effusions and 
empyemas can a benefit from intrapleural fibrinolytic 
therapy and that all such patients warrant a trial of 
intrapleural thrombolytics prior to committing to surgical 
intervention. This approach may reduce the cost and 
morbidity. 
The variability in outcomes of intrapleural fibrinolytics 
in the literature can be attributed to inconsistent study 
characteristics (6). For example, the criteria for the use of 
fibrinolytics, dose, timing of the doses, variation of chest 
tubes, and indications for surgery were not standardized 
in many of the studies. In addition, patients who received 
intrapleural fibrinolytics in many of the prior studies may 
have been poor surgical candidates who would not have 
survived a surgical treatment, such as thoracoscopic or open 
thoracotomy approach. 
We present the largest, consecutive series to date of 
complex pleural effusions treated with alteplase. We 
utilized a low dose with once daily administration that 
did not result in any bleeding events. This was associated 
with a very low proportion of patients requiring salvage 
decortication. Fibrinolytic therapy has been associated 
with lower hospital costs, decreased pain, and minimal 
complications. Some patients may not respond to treatment 
with fibrinolytic therapy, and at that point surgical therapy 
may be appropriate for further treatment. Further studies 
are needed to determine the effect of dose, dwell time and 




Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical  Statement:  The study was approved by an 
institutional review board (No. 5130004) and a waiver of 
informed consent was approved by the IRB.
References
1. Thommi G, Shehan JC, Robison KL, et al. A double blind 
randomized cross over trial comparing rate of decortication 
and efficacy of intrapleural instillation of alteplase vs 
placebo in patients with empyemas and complicated 
parapneumonic effusions. Respir Med 2012;106:716-23. 
2. Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled 
trial of intrapleural streptokinase for pleural infection. N 
Engl J Med 2005;352:865-74. 
3. Light RW. A new classification of parapneumonic effusions 
and empyema. Chest 1995;108:299-301. 
4. Chen JS, Huang KC, Chen YC, et al. Pediatric empyema: 
outcome analysis of thoracoscopic management. J Thorac 
Cardiovasc Surg 2009;137:1195-9.
5. Froudarakis ME, Kouliatsis G, Steiropoulos P, et 
al. Recombinant tissue plasminogen activator in the 
treatment of pleural infections in adults. Respir Med 
2008;102:1694-700.
6. Hamblin SE, Furmanek DL. Intrapleural tissue 
plasminogen activator for the treatment of parapneumonic 
effusion. Pharmacotherapy 2010;30:855-62.  
7. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy 
versus conservative management in the treatment of 
adult parapneumonic effusions and empyema. Cochrane 
Database Syst Rev 2008;(2):CD002312. 
8. Stefanutti G, Ghirardo V, Barbato A, et al. Evaluation of 
a pediatric protocol of intrapleural urokinase for pleural 
empyema: a prospective study. Surgery 2010;148:589-94.
9. Ben-Or S, Feins RH, Veeramachaneni NK, et al. 
Effectiveness and risks associated with intrapleural 
alteplase by means of tube thoracostomy. Ann Thorac 
1316 Heimes et al. Thrombolytics
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(5):1310-1316jtd.amegroups.com
Surg 2011;91:860-3; discussion 863-4.  
10. Sonnappa S, Cohen G, Owens CM, et al. Comparison of 
urokinase and video-assisted thoracoscopic surgery for 
treatment of childhood empyema. Am J Respir Crit Care 
Med 2006;174:221-7.
11. Gates RL, Hogan M, Weinstein S, et al. Drainage, 
fibrinolytics, or surgery: a comparison of treatment options 
in pediatric empyema. J Pediatr Surg 2004;39:1638-42.
12. Rahman NM, Maskell NA, West A, et al. Intrapleural 
use of tissue plasminogen activator and DNase in pleural 
infection. N Engl J Med 2011;365:518-26.
13. St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic 
decortication vs tube thoracostomy with fibrinolysis for 
empyema in children: a prospective, randomized trial. J 
Pediatr Surg 2009;44:106-11; discussion 111.
Cite this article as: Heimes J, Copeland H, Lulla A, Duldulao 
M, Bahjri K, Zaheer S, Wallen JM. The use of thrombolytics in 
the management of complex pleural fluid collections. J Thorac 
Dis 2017;9(5):1310-1316. doi: 10.21037/jtd.2017.04.56
